. Author manuscript; available in PMC: 2015 Apr 13.

Published in final edited form as: Pharm Res. 2013 Mar 13;30(6):1471–1482. doi: 10.1007/s11095-012-0953-8

Table I. PK Parameters of P-S After Topical and Oral Application.

Delivery route	Metabolite	C_max nmole/g		T_max h		AUC_0–24h (nmole/g)*h		Sum of AUC_0–24h (nmole/g)*h

				Muscle/blood
Topical	P-S	680	2	1	4	4109	17	4697	784
	Sulindac	31	18	2	8	399	245
	S.sulfide	2	10	4	8	18	122
	S.sulfone	12	23	24	8	170	400
Oral	P-S	11	2	0.5	0.5	49	18	1266	1472
	Sulindac	20	33	8	2	296	405
	S.sulfide	13	13	8	8	158	156
	S.sulfone	40	52	8	8	764	405

PS was administered topically and orally in equal doses. Values are the average of two; Individual values were within <9% of each other